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Through cDNA microarray analysis of gene expression in human cochlea and vestibule, we detected strong ex-
pression of m-crystallin (CRYM; also known as “NADP-regulated thyroid hormone-binding protein”) only in these
inner-ear tissues. In a subsequent search for mutations of CRYM, among 192 patients with nonsyndromic deafness,
we identified two mutations at the C-terminus; one was a de novo change (X315Y) in a patient with unaffected
parents, and the other was a missense mutation (K314T) that segregated dominantly in the proband’s family. When
the mutated proteins were expressed in COS-7 cells, their subcellular localizations were different from that of the
normal protein: the X315Y mutant showed vacuolated distribution in the cytoplasm, and the K314T mutant
localized in perinuclear areas, whereas normal protein was distributed homogeneously in the cytoplasm. Aberrant
intracellular localization of the mutated proteins might cause dysfunction of the CRYM product and result in
hearing impairment. In situ hybridization analysis using mouse tissues indicated its expression in the lateral region
of the spiral ligament and the fibrocytes of the spiral limbus, implying its possible involvement in the potassium-
ion recycling system. Our results strongly implicate CRYM in normal auditory function and identify it as one of
the genes that can be responsible for nonsyndromic deafness.
Introduction
Hearing loss that disturbs normal communication is a
common sensory disorder worldwide. The incidence of
congenital deafness is ∼1 in 1,000 newborns, and half
of those cases are thought to result from genetic factors
(Marazita et al. 1993). Most congenital or childhood-
onset hearing impairments are nonsyndromic. So far,
170 genetic loci linked to nonsyndromic deafness have
been described, and 26 genes whose mutations can cause
deafness have been cloned (Hereditary Hearing LossHo-
mepage). Those data indicate that deafness is a highly
heterogeneous disorder, and that genes responsible for
deafness encode a large diversity of molecules. However,
little is known of the molecular basis of inner-ear func-
Received August 22, 2002; accepted for publication October 1,
2002; electronically published December 6, 2002.
Dr. Yusuke Nakamura, Laboratory of Molecular Medicine, Human
Genome Center, Institute of Medical Science, The University of Tokyo,
4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. E-mail: yu-
suke@ims.u-tokyo.ac.jp
Nucleotide sequence data reported herein are available in the DDBJ/
EMBL/GenBank databases; for details, see the Electronic-Database
Information section of this article.
 2003 by The American Society of Human Genetics. All rights reserved.
0002-9297/2003/7201-0008$15.00
tion, because the tissues in question are too small to be
investigated in detail. The classical genetic approach
through linkage analysis has limitations because the
causes of deafness are so heterogeneous, and because
linkage analysis requires DNA from a relatively large
number of affected and unaffected members in a single
family. Hence, we need to establish an effective alter-
native approach to searching for as-yet-unidentified
genes that may be involved in hearing loss.
Obviously, genes that are expressed specifically in au-
ditory tissues are likely to be good candidates to screen
for genetic alterations in patients with deafness. In fact,
several genes associated with deafness have been effi-
ciently identified by way of organ-specific approaches
involving, for example, subtractive human and mouse
cDNA cochlear libraries (Robertson et al. 1994; Yasun-
aga et al. 1999; Simmler et al. 2000; Verpy et al. 2000).
Several databases are now available which contain in-
formation about genes expressed in cochlea or in the
developing ear (Morton Cochlear EST Database, Table
of Gene Expression in the Developing Ear Web site, and
Corey Lab Inner Ear Gene Expression Database).
It follows that identification of transcripts specific to
the inner ear should also be helpful for studying hearing
disorders. Therefore, in the work reported here we ap-
Table 1
Genes Preferentially Expressed in the Inner Ear with a Cy3/Cy5 Ratio of 110
GENBANK
ACCESSION
NO.
Cy3/Cy5 RATIO IN
DESCRIPTION LOCUS
CORRESPONDENCE WITH
DEAFNESS LOCUSCochlea Vestibule
AA669336 156.51 136.15 Coagulation factor C homology (cochlin, COCH) 14q12-q13
L02950 119.55 59.74 m-crystallin (CRYM) 16p13.11-p12.3
M61901 114.30 70.40 Prostaglandin D synthase 9q34.2-34.3 DFNB33 (9q34.3)
NM_020157 79.87 27.51 Otoraplin 20p12.1-p11.23 Cochlear genea
NM_003460 77.36 185.57 Zona pellucida glycoprotein 2 (sperm receptor) 16p12
M64722 69.52 104.29 clusterin (TRPM-2, apolipoprotein J) 8p21-p12
J02611 68.59 108.76 Apolipoprotein D 3q26.2-qter
XM_051860 56.54 22.55 KIAA1199 protein 15q24
W39428 55.10 67.96 F-box only protein 2 1p36.23
AA972852 43.41 45.94 Retinol-binding protein 1, cellular 3q23 DFNB15 (3q21-25/19p13)
J05096 41.98 55.99 ATPase, Na/K transporting, alpha 2 () polypeptide 1q21-q23 DFNA7 (1q21-q23)
AA252389 38.77 54.70 Lipoma HMGIC fusion partner 13q12
AA292179 37.41 16.65 Ubiquitin A-52 residue ribosomal protein fusion product 1 19p13.1-p12 DFNB15 (3q21-25/19p13)
M62402 30.46 44.97 Insulin-like growth factor binding protein 6 12q13
AF039699 30.22 22.61 USH1C 11p14.3
X99920 26.20 70.30 S100 calcium-binding protein A13 1q21 DFNA7 (1q21-q23)
U59832 26.04 13.68 Forkhead box D1 5q12-q13
X53331 23.79 16.19 Matrix Gla protein 12p13.1-p12.3
J02984 21.92 10.26 Ribosomal protein S15 19p-tel
X06617 20.19 17.83 Ribosomal protein S11 19q13.3 DFNA4 (19q13)
X75450 18.48 19.39 Melanoma inhibitory activity (SH3 domain) 19q13.32-q13.33 DFNA4 (19q13)
AA308743 17.91 11.85 Ribosomal protein L35 9q34.1
AA526377 17.90 10.60 Ribosomal protein L15 19q13.3 DFNA4 (19q13)
AA496786 17.64 33.33 Collagen, type IX, alpha 3 20q13.3
X96484 16.42 11.71 DiGeorge syndrome critical region gene 6 22q11.21
AA058578 16.00 46.30 Homo sapiens cDNA FLJ10158 fis 3q12.3-21.3 DFNB15 (3q21-25/19p13)
U14970 15.76 12.25 Ribosomal protein S5 19q13.4 DFNA4 (19q13)
AF052685 15.27 10.71 Protocadherin gamma subfamily C, 3 5q32
F22593 15.27 34.13 Vesicle-associated membrane protein 5 (myobrevin) 2p11.2
W73992 15.15 11.10 Serologically defined colon cancer antigen 43 9q22.2
AA633908 15.00 11.10 ESTs 20p12
X03342 14.89 15.31 Ribosomal protein L32 3q13.3-q21
AA205528 14.79 14.90 Carbonic anhydrase XIV 1q21 DFNA7 (1q21-q23)
AI344213 14.28 21.21 Copper chaperone for superoxide dismutase 11q13
AA057243 13.00 10.90 PH domain containing protein in retina 1 11q13.5-q14.1
AA434038 12.96 11.83 Gap junction protein, beta 2, 26kD (connexin 26) 13q11-q12
AA148265 12.60 12.00 Ribosomal protein L21 13q12.13
W84565 12.50 10.60 Secreted protein of unknown function 1q32.3
AI268685 12.33 11.38 HSPC023 protein 19p13.13 DFNB15 (3q21-25/19p13)
AY043487 12.22 29.28 Selenoprotein SelM (SELM) 22q12
S72043 11.95 13.10 Metallothionein 3 (growth inhibitory factor
[neurotrophic])
16q13
AF284751 11.90 12.00 Hypothetical protein HT036 1q34.1
X54412 11.88 35.98 Collagen, type IX, alpha 1 6q12-q14
T55019 11.83 17.47 Ribosomal protein L28 19q13.4 DFNA4 (19q13)
AB003184 11.60 30.36 Immunoglobulin superfamily containing leucine-rich
repeat
15q23-q24
X89401 11.43 20.16 Ribosomal protein L21 13q12.13
AA625532 11.37 14.36 Discoidin domain receptor family, member 2 1q12-q23 DFNA7 (1q21-q23)
M68864 10.88 16.00 ORF 11cen-q12.1
AI240945 10.60 13.80 Ubiquitously transcribed tetratricopeptide repeat gene, Y
chromosome
Yq11
AA446913 10.51 13.71 Ubiquitin specific protease 11 Xp21.2-p11.2
N71750 10.46 26.54 Zinc-finger protein 288(BC015587) 3q13
X13916 10.31 17.43 Low density lipoprotein-related protein 1 (alpha-2-macro-
globulin receptor)
12q13-q14
a Otoraplin (OTOR [MIM 606067]) has been identified from a human fetal cochlear. So far, there is no report for human deafness-causing mutation.
Abbreviations: DFNA, autosomal dominant loci; DFNB, autosomal recessive loci.
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Figure 1 Analysis and confirmation of cDNAmicroarray results.
A, Signals of CRYM in the microarray (white arrows). aRNA from
the human inner ear (cochlear and vestibular tissues) was labeled with
Cy3-dCTP (red); mixed aRNA from 29 other tissues yielded green
signals from Cy5-dCTP (green). B, Confirmation of microarray data
by semiquantitative RT-PCR of CRYM with one-round amplified
RNAs.
Table 2
Nonsyndromic Deafness Gene Expression in the Cochlea and Vestibule by cDNA
Microarray Analysis
GENE
Cy3/Cy5 RATIO IN
ASSOCIATION WITH HUMAN DEAFNESSCochlea Vestibule
COCH 156.51 136.15 DFNA9
GJB2 (Cx26) 12.96 11.83 DFNB1/DFNA3/deafness with skin disorders
GJB6 (Cx30) 34.71 4.55 DFNB1/DFNA3
USH1C 30.22 22.61 DFNB18/Usher syndrome type 1C
MYO7A 6.20 3.63 DFNB2/Usher syndrome type 1B
MYH9 1.50 1.00 DFNA17/Epstein and Fechtner syndrome
MYO6 1.20 1.60 DFNA22
CLDN14 No signal No signal DFNB29
POU3F4 No signal No signal DFN3
NOTE.—MIM numbers are as follows: DFNA9 (MIM 601369), DFNB1 (MIM
220290), DFNA3 (MIM 601544), deafness with skin disorders (MIM 148350), DFNB18
(MIM 602092), Usher syndrome type 1C (MIM 605242), DFNB2 (MIM 600060), Usher
syndrome type 1B (MIM 6276903), DFNA17 (MIM 03622), Epstein and Fechtner syn-
drome (MIM 153650), DFNA22 (MIM 606344), DFNB29 (MIM 60568), and DFN3
(MIM 304400).
plied a genome-wide cDNA microarray analysis to in-
vestigate gene-expression profiles in human cochlea and
vestibule, and focused on one of the genes that was
expressed at high levels in both of those tissues. Mutant
alleles of this gene were responsible for nonsyndromic
deafness in two individuals among the group of pro-
bands we studied.
Family, Material, and Methods
Preparation of Tissues and RNA
Tissues from one cochlea and seven vestibules were
obtained with written informed consent from different
adult patients undergoing labyrinthectomy; each patient
had been diagnosed with a nonlabyrinthine disorder,
such as temporal-bone tumor or acoustic tumor.
Total RNA was extracted from each inner-ear sample
using Trizol (Life Technologies) according to the man-
ufacturer’s instructions. After treatment with DNase I,
T7-based RNA amplification was performed as de-
scribed elsewhere (Luo et al. 1999), with some modifi-
cations. Using an estimated 3 ng of total RNA from the
cochlear tissue, we performed three rounds of amplifi-
cation. For vestibular tissues, we performed two rounds
of RNA amplification, using 3 mg of total RNA. We
obtained 70–80 mg of each amplified RNA (aRNA) sam-
ple. As a control, we mixed PolyA() RNAs derived
from 29 normal human tissues (bone marrow, brain,
heart, kidney, liver, lung, lymph node, mammary gland,
pancreas, placenta, prostate, salivary gland, skeletal
muscle, small intestine, spinal cord, spleen, stomach, tes-
tis, thymus, thyroid, trachea, uterus, fetal brain, fetal
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Table 3
Nucleotide Changes Detected by Mutation Analyses in the CRYM Gene
CHANGE
EXON/
INTRON AMINO ACID
FAMILY
NO.
ALLELE FREQUENCY
in Patients in Control Subjects
IVS1-116CrT Intron1 90/364 Not done
IVS1-119GrA Intron 1 3/364 Not done
IVS438CrG Intron 4 84/336 .12a
864GrC Exon 7 Thr288Thr 94/330 Not done
941ArC Exon 8 Lys314Thr 12 1/384 0/192
945ArT Exon 8 X315Tyr r extended protein 1 1/384 0/192
a See “A Database of Japanese Single Nucleotide Polymorphisms” Web site.
Figure 2 Pedigrees and electrophoregrams showing mutations in the CRYM gene in two families. Corresponding normal sequences are
shown in the left-hand panels. A, In family 1, only patient II-2 shows a heterozygous ArT substitution, changing the stop codon to a Tyr
residue and bringing about an extension of the protein by five amino acids at the C-terminal. B, In family 12, the patient (II-1) and her affected
mother (I-2) are both heterozygous for a Lys314Thr mutation.
kidney, fetal liver, fetal lung [Clontech], colon, ovary
[Biochain], and mesenteric adipose tissue).
cDNA Microarray
Microarray slides containing 23,040 cDNA spots se-
lected from the UniGene database of theNational Center
for Biotechnology Information were utilized for our
analysis of gene expression in the human inner ear. As
described elsewhere (Ono et al. 2000; Saito-Hisaminato
et al. 2002), aRNAs from each tissue sample (2.5–5 mg)
were labeled with Cy3-dCTP (Amersham Pharmacia
Biotech), and an equal amount of aRNAs from amixture
of 29 human tissues was labeled with Cy5-dCTP (Amer-
sham Pharmacia Biotech). Labeling and hybridization
were performed according to protocols noted elsewhere
(Ono et al. 2000). The intensity of each hybridized spot
was measured and analyzed with the ArrayVision com-
puter program (Amersham Bioscience), and background
signals were subtracted. Each Cy3- andCy5-fluorescence
intensity was normalized by use of averaged signals from
52 housekeeping genes. We calculated a cut-off value for
each gene’s expression to dissolve background fluctua-
tion, according to parameters established previously
(Saito-Hisaminato et al. 2002).
RT-PCR
To confirm our cDNA microarray data we performed
semiquantitative RT-PCR experiments using cDNAs de-
rived from the vestibule and from the 29 normal tissues,
using single-round aRNAs. GAPDH served as an inter-
nal control. The amount of cDNA, as judged by the
intensity of the GAPDH signal, was optimized in both
samples. Primers used to amplify specific CRYM gene
products were F: TCTGGAGATGTCCTGCTGTC and
R: GGCTACCTAGCTTTGCTTTC; the PCR proceeded
for 25 cycles of 95C for denaturing, 55C for annealing,
and 72C for extension. The PCR products were elec-
trophoresed on a 2% agarose gel and were visualized
by ultraviolet light.
Family Selection and Mutational Search
We screened DNA from 192 Japanese families in
which probands were found to have congenital or child-
hood-onset bilateral nonsyndromic sensorineural hear-
ing loss and no history of drug toxicity, infections or
injury. Of these families, 41 showed dominant inheri-
tance of deafness and 21 showed recessive inheritance;
the other 130 were represented by only one affected
individual (simplex cases). Each patient was clinically
well characterized by a series of auditory examinations
(pure-tone audiometry) that indicated sensorineural
hearing loss ranging from mild to profound in severity.
All participants in the project had provided written in-
formed consent and had already been examined for mu-
tations in the GJB2 gene [MIM 121011] and the mi-
tochondrial gene encoding 12S rRNA [MIM 561000],
but no mutations were detected in either of those genes
although both had been described as common causes of
deafness (Abe et al. 2000; Usami et al. 2000). On the
basis of our microarray results, we analyzed genomic
DNA isolated from peripheral blood leukocytes of one
affected member of each family for mutations in the
CRYM gene (MIM 123740).
We determined the genomic structure of the CRYM
gene by comparison with a BAC sequence (GenBank
accession number AF001550) on chromosome 16. We
amplified each of its eight exons and their flanking in-
tronic sequences using the following oligonucleotide
primers: F1, AGGCTGGGCTGTGACCAGCA; R1,
AGCTGTTAGCAA CGGTTAGG; F2, TGTCTAAG-
GGAAGGGCAGAG; R2, TGTTGCTGGTATCCAG-
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Figure 3 Fluorescent images of COS-7 cells expressing HA-tagged CRYM proteins. Nuclei are counterstained with DAPI (blue). Cells
representative of six independent experiments are shown at a magnification of 60#. Subsequently, the numbers of cells were counted in 8–10
randomly selected fields (60#) using fluorescence microscopy (Nikon) at 24 h, 48 h, 72 h, and 96 h, respectively. A, Wild-type (WT) CRYM
protein (green) localizes to cytoplasm diffusely throughout the time course of the experiments. B, The X315Y mutant with an extended C-
terminal tail leads to vacuolated cytoplasmic distribution. The K314T mutant protein is localized predominantly in the perinuclear area.
TCAC; F3, AGGAATCGGATCCAGGTCTGA; R3,
TCTGGAGTTCCAGCTATGTC; F4, ATTGCCTGC-
AAGCTCTTGAG; R4, CCTGACTCTTATCCTCC-
ATC; F5, CGGTCTCATCAAGTTGAAAGG; R5,
CTGCACCCAGCCAAATATTG; F6, GGGAATGA-
GGGGGTATTTTG; R6, GCCCATATTTTTCTGGA-
ATGG; F7, CAGTGTACAAAGGATCTCTC; R7,
TGACCTGAATGATGGAGCAC; F8, TAGGCATT-
GGCAACATGGAC; and R8, GGTAGAACAGAA-
GAAATGGC.
Each genomic DNA (5–10 ng) was amplified by the
PCR, using Ex-Taq polymerase (Takara), for 2 min at
95C, followed by 37 cycles of 95C for 30 s, 56C for
30 s, and 72C for 50 s, with a final extension of 5 min.
After the products were purified by Multiscreen PCR
(MILLIPORE), we performed standard cycle-sequencing
reactions in an ABI 3700 autosequencer. DNA samples
from 96 unrelated Japanese volunteers with normal
hearing were used as controls.
Epitope Tagging of CRYM
To obtain constructs expressing the wild-type CRYM
protein, as well as the X315Y and K314T variants, we
PCR amplified the corresponding parts of the CRYM
cDNA sequence (GenBank accession number NM_
001888), using KOD-Plus-DNApolymerase (Toyobo)
and the following primer sequences: (1) a W-Tag-F for-
ward primer common to the wild type and bothmutants,
containing sequence corresponding to HA-tag (5′-CGT-
GAATTCCAGACCGTGCATCATGTACCCATACGA-
CGTCCCAGACTACGCTAGCCGGGTACCAGCGT-
TCC-3′); and (2) reverse primers W-R (5′-AAGCTC-
GAGTTATTTACCAGATGACCAGGAATCA-3′) for
the wild type, M(1)-R (5′-AAGCTCGAGTCAAGT
TCCTTTGTTATATTTACCAG-3′) for the X315Y mu-
tant, and M(2)-R (5′-AAGCTCGAGTTATGTACCAG-
ATGACCAGGAATC-3′) for the K314T mutant. PCR
products were cloned into the pcDNA 3.1() vector
(Invitogen).
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Figure 4 In situ hybridization analysis of Crym expression. The mouse cochlea reveals distinct labeling by the Crym antisense probe
(arrows). Crym mRNA expression in the fibrocytes of spiral ligaments (SLg) and the fibrocytes of spiral limbus (SLm) in all turns of the mouse
cochlea. Control hybridization was performed with a sense probe on consecutive tissue sections.
Microscopic Analysis of Immunofluorescence
For transfection of COS-7 cells, we used 1 mg of each
construct and 3 ml of FuGENE6 (Roche Molecular
Biochemicals) diluted in OPTIMEM medium (Gibco
BRL) according to the manufacturer’s instructions. In
two-well glass chamber slides, 1# 104 to 5# 104 cells
were seeded. Cell samples were fixed 24 h, 48 h, 72 h,
and 96 h after transfection and were treated as described
elsewhere (Tsujikawa et al. 1999). They were first in-
cubated overnight at 4C with mouse anti-HA tag an-
tibody (1:1,500) (Santa Cruz) and then for 60 min at
25C with FITC-conjugated goat anti-mouse IgG (1:
3,000) (ICN/Cappel). Images were viewed by means of
fluorescence microscopy. We examined a total of six in-
dependent experiments.
In Situ Hybridization
The mouse cochlea at postnatal days (Pn) P0 was dis-
sected, was fixed by 10% neutral formalin, and was
embedded in paraffin. Tissue sections (4 um) were de-
waxed and hybridized as described elsewhere (Hoshino
et al. 1999), with some modifications. A 701-bp DNA
fragment corresponding to the nucleotide positions
260–960 of mouse Crym cDNA (GenBank accession
number NM_016669) was subcloned into pBlueScript
SK() vector (Stratagene) and was used for generation
of sense or antisense RNA probes. We carried out hy-
bridization with digoxigenin-labeled RNA probes at
42C for 18 h. The bound label was detected using NBT-
BCIP, an alkaline phosphatase color substrate, and tissue
slides were stained with Kernechtrot stain solution.
Results
Verification of cDNA Microarray Data
Through analysis of expression profiles of human in-
ner-ear tissues on a cDNAmicroarray containing 23,040
genes, we found 52 genes whose signal intensities were
more than 10-fold higher in cochlea and vestibule than
in a mixture of 29 other tissues (table 1). Of the 52 genes
expressed preferentially in the inner ear, 14 were located
in one of five chromosomal regions known to contain
loci linked to human deafness (DFNA4 [MIM 600652],
DFNA7 [MIM 601412], DFNB15 [MIM 601869], and
DFNB33 [MIM 607239]). Among nine genes known to
be responsible for nonsyndromic deafness (COCH
[MIM 603196], GJB2, GJB6 [MIM 604418], MYO7A
[MIM 276903], USH1C [MIM 605242], MYH9 [MIM
160775], MYO6 [MIM 600970], CLDN14 [MIM
605608], and POU3F4 [MIM 300039]) that were pre-
sent in our array, we confirmed expression in the inner
ear of all except CLDN14 and POU3F. Five of these
seven genes showed relatively high levels of expression
(ratio 15 compared with the control) in the cochlea and
of those, four (COCH, GJB2, GJB6, and USH1C) were
considered to be expressed specifically or preferentially
(ratio 110) (table 2). Among the genes specifically or
preferentially expressed in the inner ear, we focused on
CRYM because it represented the second-highest Cy3/
Cy5 ratio, afterCOCH: 119.55 in the cochlea and 59.74
in the vestibule (table 1; fig. 1A). We confirmed pre-
dominant expression of CRYM in the inner ear by se-
miquantitative RT-PCR (fig. 1B) and considered this
gene to be a candidate for playing an important role in
auditory function.
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Mutational Analyses
We analyzed the CRYM gene for mutations in 192
patients with nonsyndromic hearing loss. Direct DNA
sequencing identified four genetic polymorphisms in this
panel: one mutation in exon 8, causing an amino acid
substitution, and one mutation affecting the stop codon
(table 3). The latter mutation (X315Y; 945ArT) caused
addition of five amino acids at the C-terminal end of
the protein. This mutation was detected only in the pro-
band, not in either of his unaffected parents or in his
brother (family 1; fig. 2A). We confirmed paternity and
maternity in family 1, using 12 highly polymorphic mi-
crosatellite markers (data not shown), and concluded
that this mutation had occurred de novo.
The other mutation, K314T (941ArC), was detected
in the proband and her affected mother in family 12 (fig.
2B). Although the unaffected father was not available
for testing, the mutation appeared to cosegregate with
hearing loss. To exclude a possibility that this alteration
represented a polymorphism, we examined 192 control
chromosomes but did not find the substitution in any of
them.
Clinical Analyses
Affected individuals with the X315Y and the K314T
mutations have normal stature and intelligence. There
is no vestibular, visual, renal, or muscular involvement
for all affected individuals with the CRYM mutations.
Hearing impairment has been identified in the individual
with mutation X315Y at age 19 mo. Auditory brainstem
responses (ABR), conditioned orientation reflex audi-
ometry, and pure tone audiometry examinations showed
bilateral moderate sensorineural hearing loss (average
50–60 dB) affecting all frequencies by a down-sloping
shaped audiogram pattern. Hearing loss progressed from
moderate to severe (70 dB), bilaterally at age 13 years,
and subsequent Carolic test has shown normal vestibular
function. The age at diagnosis of hearing loss in affected
members with the other K314T missense mutation has
been documented as being 1 year. The K314T case
showed bilateral severe (80–90 dB) sensorineural hear-
ing loss affecting all frequencies with no progression.
Temporal bone CT scan was performed for all affected
individuals carrying a CRYM mutation, but no abnor-
mal findings were observed.
Subcellular Localization of Mutant Proteins
To examine the consequences of CRYM mutations,
we expressed HA-tagged wild-type CRYM protein, as
well as variants corresponding to each of the two mu-
tations in COS-7 cells. Expression of all three proteins
was confirmed by western blotting of protein extracts
from transfected cells with mouse anti-HA antibodies.
Fluorescent microscopy revealed diffuse cytoplasmic
staining in cells transfected with thewild-type expression
construct, and, 24 h and 48 h after transfection, the
subcellular localizations of both mutant proteins were
similar to the distribution of wild-type protein.However,
72 h and 96 h after transfection, we observed different
patterns in significant proportions of transfected cells
(fig. 3); the wild-type protein still revealed diffuse cy-
toplasmic distribution, but nearly 20% of the cells ex-
pressing the X315Y mutant revealed a vacuolation pat-
tern in the cytoplasm, and approximately one-fourth of
those expressing the K314Tmutant showed strong stain-
ing, predominantly in perinuclear regions. The aberrant
staining patterns were observed in almost none of the
cells expressing wild-type protein.
Expression Analysis of Crym in the Mouse Cochlea
To study a possible biological function of CRYM, we
cloned mouse Crym cDNA and performed an in situ
hybridization experiment using mouse tissue. As shown
in fig. 4A, hybridization signals with the Crym probe
were observed in the lateral fibrocytes of the spiral lig-
aments (SLg) and the fibrocytes of the spiral limbus
(SLm), whereas no in situ hybridization signal was de-
tected with the control sense RNA probe (fig. 4B). Crym
expression was not detected in neurosensory epithelium
such as inner and outer hair cells.
Discussion
To explore molecules essential for auditory function and
to isolate genes responsible for deafness, we analyzed
expression profiles of human inner-ear tissues on a
cDNA microarray. The cochlea (for sound detection)
and vestibule (for balance) have the same origin in the
developmental process and possess similar properties
both structurally and physiologically. We identified a set
of 52 genes that were specifically or preferentially ex-
pressed in the inner ear and are investigating their pos-
sible roles in patients with nonsyndromic deafness.
Among nine known nonsyndromic deafness genes that
were present on our microarray, seven were confirmed
to be expressed in the inner ear by our microarray anal-
ysis. Four of them, COCH, GJB2, GJB6, and USH1C,
showed high Cy3/Cy5 ratios (110) as compared with
other tissues, indicating specific expression in the inner
ear; one additional gene, MYO7A, revealed a relatively
high Cy3/Cy5 ratio (6.20) in the cochlea. These results
indicated that screening genes that are highly expressed
in the inner ear might be an efficient approach to iden-
tifying aberrant molecules involved in deafness.
By screening DNA from a panel of patients with non-
syndromic deafness for mutations in CRYM, a gene that
was especially abundant in the inner ear, we found pos-
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sible disease-causing mutations in two cases. In one fam-
ily, only the proband carried a mutation (X315Y), in-
dicating that this change had arisen de novo in the
affected individual, adding five amino acids at the C-
terminal end of the CRYM protein. Mutations of a sim-
ilar type have been reported as causes of some other
hereditary conditions (Arlt et al. 1994; Marr et al.
2002). We underscored the deafness-causing potential
of the X315Y mutation by demonstrating aberrant sub-
cellular localization of the mutant protein.
The other mutation caused a nonconservative amino
acid change of lysine to threonine at codon 314. Since
the lysine residue at this position is conserved across
mammalian species—including human, mouse, rat, and
marsupial—according to alignments of human CRYM
sequence with those of other mammals (human m-crys-
tallin [GenBank accession number Q14894], mouse m-
crystallin [GenBank accession number NP_057878], rat
m-crystallin [GenBank accession number NP_446407]
and kangaroo m-crystallin [GenBank accession number
Q28488]), we assume that the K314T mutation would
introduce a significant change in protein structure. Ab-
errant intracellular localization of the corresponding
mutant protein supported the importance of this residue
in human CRYM. Our findings imply that both mu-
tations at the C-terminal end are likely to have dele-
terious effects on CRYM function. Although the precise
mechanisms of these mutational effects remain to be
determined, we consider that both of the heterozygous
mutations we detected in the CRYM gene in deaf pa-
tients are likely to have affected auditory function, prob-
ably in a dominant-negative manner.
CRYM is one of the taxon-specific crystallins and is
also called “m-crystallin.” It was first identified as a
major structural protein of the ocular lens in some mar-
supials (Kim et al. 1992). CRYM mRNA expression in
fetal cochlea has been also demonstrated in the Morton
Cochlear EST Database (GenBank accession number
N73414). Although expression of CRYM is not abso-
lutely specific to the inner ear, our microarray results
indicate that its product is extremely abundant in the
cochlea and vestibule. Initially, the predicted amino acid
sequence showed similarity to the ornithine cyclodeam-
inase (OCD) and to glutamyl-tRNA reductase (gluTR)
of bacteria and plants; both of these proteins represent
a diverse superfamily of enzyme. The similarity sug-
gested to some that m-crystallin might perform an en-
zymatic rather than a structural role in lens tissue (Kim
et al. 1992; Segovia et al. 1997). However, now it is
thought to be a cytosolic NADP-regulated thyroid hor-
mone-binding protein (THBP), a member of a group of
molecular entities responsible for most of the intracel-
lular high-affinity binding of T3 and T4 (Vie et al.
1997). THBPs are involved in sequestration and release
of intracellular thyroid hormones (homeostasis).
Whereas the cytosolic binding sites for T3 and T4 are
similar to those of thyroid hormone receptors (TRs),
the binding activity of THBPs is 100 times greater than
that of TRs (Vie et al. 1997). Therefore, we speculate
that mutant CRYM could abrogate the affinity of thy-
roid hormone, an essential agent for development of the
auditory system. Cochlear structures are extremely vul-
nerable to thyroid-hormone deficiency during critical
developmental periods; such deficiency results in defec-
tive morphological differentiation andmaturation in the
organ of Corti (Uziel 1986).
In the mouse, Crym was expressed in the cochlea and
uticle at P2 and P32 stages (Corey Lab Inner Ear Gene
Expression Database). We detected localization of Crym
mRNA in two distinct tissues of mouse cochlea; the lat-
eral fibrocytes of the spiral ligaments and the spiral lim-
bus fibrocytes (fig. 4A). The postulated roles for these
cells are thought to be K circulation/K recycling (Spicer
and Schulte 1996; Steel and Kros 2001), suggesting that
CRYM dysfunction may be interfering with potassium
ion recycling, thus disturbing its maintenance of K rich
endolymph and a positive electrical potential. We hy-
pothesize that dysfunction of m-crystallin may cause crit-
ical morphogenetic abnormalities of the labyrinth in-
duced from thyroid-hormone deficiency and synergic
auditory dysfunction involved in ionic homeostasis.
In conclusion, our results demonstrate that mutations
of CRYM can be responsible for nonsyndromic deafness
and that using the cDNA microarray approach to iden-
tify genes expressed specifically in the inner ear may be
an efficient means of determining other good candidates
for involvement in nonsyndromic deafness.
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